The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets.

Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase II clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases.